Microvascularization and expression of VEGF and its receptors in recurring meningiomas: Pathobiological data in favor of anti-angiogenic therapy approaches

Clinical Neuropathology

Volumn 31, Issue 5, 2012, Pages 352-360

  Preusser, Matthias ^a,b   Hassler, Marco ^a,b   Birner, Peter ^b   Rudas, Margaretha ^b   Acker, Till ^c,d   Plate, Karl H ^c   Widhalm, Georg ^b   Knosp, Engelbert ^b   Breitschopf, Helene ^e   Berger, Johannes ^b,e   Marosi, Christine ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e Medical University of Vienna   (Austria)

Author keywords

Antiangiogenesis; Immunohistochemistry; In situ hybridization; Meningioma; Microvessel density

Indexed keywords

ANGIOGENESIS INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ANTIANGIOGENIC THERAPY; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MENINGIOMA; MICROVASCULARIZATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT DISEASE; SKULL BASE TUMOR; TUMOR VASCULARIZATION;

ADULT; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETROSPECTIVE STUDIES; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867593353     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/NP300488     Document Type: Article

References (43)

1. Gondi V, Tome WA, Mehta MP. Fractionated radiotherapy for intracranial meningiomas. J Neurooncol. 2010; 99: 349-356. doi:10.1007/s11060-010-0368-5 PubMed
2. Sheehan JP, Williams BJ, Yen CP. Stereotactic radiosurgery for WHO grade I meningiomas. J Neurooncol. 2010; 99: 407-416. doi:10.1007/s11060-010-0363-x PubMed
3. Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD. Medical therapies for meningiomas. J Neurooncol. 2010; 99: 365-378. doi:10.1007/ s11060-010-0349-8 PubMed
4. Kaba SE, DeMonte F, Bruner JM, Kyritsis AP, Jaeckle KA, Levin V, Yung WK. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997; 40: 271-275. doi:10.1097/00006123-199702000-00007 PubMed
5. Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang ZJ, Långström B. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methi onine positron emission tomography. Clin Cancer Res. 2001; 7: 2269-2276. PubMed
6. Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006; 24: 727-733. doi:10.1080/07357900601062339 PubMed
7. Stewart DJ, Dahrouge S, Wee M, Aitken S, Hugenholtz H. Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas. J Neurooncol. 1995; 24: 189-194. doi:10.1007/BF01078489 PubMed
8. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg. 2002; 97: 341-346. doi:10.3171/ jns.2002.97.2.0341 PubMed
9. Newton HB, Slivka MA, Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol. 2000; 49: 165-170. doi:10.1023/A:1026770624783 PubMed
10. Schrell UM, Rittig MG, Koch U, Marschalek R, Anders M. Hydroxyurea for treatment of unresectable meningiomas. Lancet. 1996; 348: 888-889. doi:10.1016/S0140-6736(05)64757-5 PubMed
11. Schrell UM, Rittig MG, Anders M, Kiesewetter F, Marschalek R, Koch UH, Fahlbusch R. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg. 1997; 86: 845-852. doi:10.3171/ jns.1997.86.5.0845 PubMed
12. Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, Fahlbusch R. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg. 1997; 86: 840-844. doi:10.3171/jns.1997.86.5.0840 PubMed
13. Cusimano MD. Hydroxyurea for treatment of meningioma. J Neurosurg. 1998; 88: 938-939. PubMed
14. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473: 298-307. doi:10.1038/nature10144 PubMed
15. Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergun S, Westphal M. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery. 2000; 46: 938-947; discussion 947-938.
16. Park K, Kim JH, Nam DH, Lee JI, Kim JS, Hong SC, Shin HJ, Eoh W, Park K. Vascular endothelial growth factor expression under ischemic stress in human meningiomas. Neurosci Lett. 2000; 283: 45-48. doi:10.1016/S0304-3940(00)00904-6 PubMed
17. Tsai JC, Hsiao YY, Teng LJ, Shun CT, Chen CT, Goldman CK, Kao MC. Regulation of vascular endothelial growth factor secretion in human meningioma cells. J Formos Med Assoc. 1999; 98: 111-117. PubMed
18. Pistolesi S, Boldrini L, Gisfredi S, De Ieso K, Camacci T, Caniglia M, Lupi G, Leocata P, Basolo F, Pingitore R, Parenti G, Fontanini G. Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study. Neuropathol Appl Neurobiol. 2004; 30: 118-125. doi:10.1046/ j.0305-1846.2003.00516.x PubMed
19. Christov C, Lechapt-Zalcman E, Adle-Biassette H, Nachev S, Gherardi RK. Vascular permeability factor/vascular endothelial growth factor (VPF/ VEGF) and its receptor flt-1 in microcystic meningiomas. Acta Neuropathol. 1999; 98: 414-420. doi:10.1007/s004010051102 PubMed
20. Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M, Fukui M. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res. 1995; 55: 1189-1193. PubMed
21. Ding YS, Wang HD, Tang K, Hu ZG, Jin W, Yan W. Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas. Ann Clin Lab Sci. 2008; 38: 344-351. PubMed
22. Panagopoulos AT, Lancellotti CL, Veiga JC, de Aguiar PH, Colquhoun A. Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol. 2008; 89: 73-87. doi:10.1007/s11060-008-9588-3 PubMed
23. Puchner MJ, Hans VH, Harati A, Lohmann F, Glas M, Herrlinger U. Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol. 2010; 21: 2445-2446. doi:10.1093/annonc/ mdq634 PubMed
24. Goutagny S, Raymond E, Sterkers O, Colombani JM, Kalamarides M. Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol. 2011; 22: 990-991. doi:10.1093/annonc/mdr012 PubMed
25. Grimm SA, Chamberlain MC, Chandler J, Muro K, Rice L, McCarthy K, Rademaker A, Helenowski IB, Johnston SK, Mrugala MM, Raizer JJ. A phase II trial of PTK 787/ZK 222584 in recurrent high grade meningioma. J Clin Oncol. 2011; 29: suppl; abstr 1046.
26. Vogelbaum MA, Leland Rogers C, Linskey MA, Mehta MP. Opportunities for clinical research in meningioma. J Neurooncol. 2010; 99: 417-422. doi:10.1007/s11060-010-0375-6 PubMed
27. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC Press; 2007.
28. Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ambros PF, Ambros IM, Bredel M, Oberhuber G, Rössler K, Budka H, Harris AL, Hainfellner JA. Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol. 2003; 13: 133-143. doi:10.1111/j.1750-3639.2003.tb00013.x PubMed
29. Preusser M, Heinzl H, Gelpi E, Hoeftberger R, Fischer I, Pipp I, Milenkovic I, Woehrer A, Popovici F, Wolfsberger S, Hainfellner JA. Ki67 index in intracranial epednymoma: a promising histopathological candidate biomarker. Histopathol. 2008; 53: 39-47. doi:10.1111/j.1365-2559.2008.03065.x
30. Schindl M, Birner P, Obermair A, Kiesel L, Wenzl R. Increased microvessel density in adenomyosis uteri. Fertil Steril. 2001; 75: 131-135. doi:10.1016/ S0015-0282(00)01642-3 PubMed
31. Breitschopf H, Suchanek G, Gould RM, Colman DR, Lassmann H. In situ hybridization with digoxigenin- labeled probes: sensitive and reliable detection method applied to myelinating rat brain. Acta Neuropathol. 1992; 84: 581-587. doi:10.1007/BF00227734 PubMed
32. Schmid S, Aboul-Enein F, Pfisterer W, Birkner T, Stadek C, Knosp E. Vascular endothelial growth factor: the major factor for tumor neovascularization and edema formation in meningioma patients. Neurosurgery. 2010; 67: 1703-1708; discussion 1708.
33. Otsuka S, Tamiya T, Ono Y, Michiue H, Kurozumi K, Daido S, Kambara H, Date I, Ohmoto T. The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas. J Neurooncol. 2004; 70: 349-357. doi:10.1007/ s11060-004-9164-4 PubMed
34. Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K. Recurrence of meningiomas. Cancer. 2000; 89: 1102-1110. doi:10.1002/1097-0142(20000901)89:5 < 1102::AID-CNCR20 > 3.0.CO;2-L PubMed
35. Ilhan A, Gartner W, Neziri D, Czech T, Base W, Hörl WH, Wagner L. Angiogenic factors in plasma of brain tumour patients. Anticancer Res. 2009; 29: 731-736. PubMed
36. Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem Soc Trans. 2003; 31: 20-24. doi:10.1042/ BST0310020 PubMed
37. Sikkema AH, de Bont ES, Molema G, Dimberg A, Zwiers PJ, Diks SH, Hoving EW, Kamps WA, Peppelenbosch MP, den Dunnen WF. Vascular endothelial growth factor receptor 2 (VEGFR-2) signalling activity in paediatric pilocytic astrocytoma is restricted to tumour endothelial cells. Neuropathol Appl Neurobiol. 2011; 37: 538-548. doi:10.1111/j.1365-2990.2011.01160.x PubMed
38. Papo N, Silverman AP, Lahti JL, Cochran JR. Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin. Proc Natl Acad Sci USA. 2011; 108: 14067-14072. doi:10.1073/pnas.1016635108 PubMed
39. Terakawa T, Miyake H, Kusuda Y, Fujisawa M. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. Urol Oncol. 2011. doi:10.1016/j. urolonc.2011.02.012 PubMed
40. Huang J, Zhang X, Tang Q, Zhang F, Li Y, Feng Z, Zhu J. Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma. J Clin Pathol. 2011; 64: 343-348. doi:10.1136/jcp.2010.085142 PubMed
41. Maiuri F, De Caro MB, Esposito F, Cappabianca P, Strazzullo V, Pettinato G, de Divitiis E. Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. J Neurooncol. 2007; 82: 63-68. doi:10.1007/ s11060-005-9078-9 PubMed
42. Barresi V, Cerasoli S, Vitarelli E, Tuccari G. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas. Acta Neuropathol. 2007; 114: 147-156. doi:10.1007/ s00401-007-0251-4 PubMed
43. Barresi V, Tuccari G. Increased ratio of vascular endothelial growth factor to semaphorin3A is a negative prognostic factor in human meningiomas. Neuropathology: official journal of the Japanese Society of Neuropathology. 2010.